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sensitivity analysis (PSA) results. METHODS: Decision analytic models were devel-
oped in Excel and R to assess the cost-effectiveness of a hypothetical therapy for a 
hypothetical, chronic disease. The models consisted of a decision tree (22 branches) 
for the ﬁrst year of therapy and of a Markov model to capture long-term costs and 
effects. Both models comprised 24 decision nodes and 6 Markov models. All costs, 
effectiveness and utility parameters were hypothetical. Probabilistic sensitivity analysis 
was used to assess decision uncertainty by performing 10 000 Monte Carlo simula-
tions. RESULTS: The incremental cost-effectiveness ratio (ICER) of the new therapy 
was $75,962.164371494/QALY when calculated with R and $75,962.164371494/
QALY when calculated with Excel. At a threshold value of $50,000 per QALY, the 
probability that the hypothetical treatment is cost-effective was 14.5% when calcu-
lated with Excel and 13.6% when using R. At the higher thresholds of $100,000 and 
$150 000 per QALY, the probabiliy estimates increased to 80.4% (Excel) and 80.6% 
(R) and 98.0% (Excel) and 98.1% (R), respectively. CONCLUSIONS: Excel and R 
allow building and analyzing complex decision models. As we showed, both model 
implementations yield the same results when calculating an ICER, up to 14 digits. The 
difference in PSA results might have been due to their probabilistic nature (here: 
10,000 iterations). Both packages have been used for medical decision making. Choos-
ing one package over the other does not need to be performance-based and can be 
left to personal preference.
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OBJECTIVES: Many cost-effectiveness analyses in rheumatoid arthritis (RA) rely on 
statistical models relating Health Assessment Questionnaire Disability Index (HAQ) 
scores to health utilities. Linear models can produce out-of-bound estimates of Health 
Utilities Index Mark 3 (HUI3) scores. We estimated bounded, nonlinear relationships 
between HAQ and HUI3 based on patient-level data. METHODS: Bayesian general-
ized linear models (GLMs) were developed to predict baseline HUI3 conditional on 
baseline HAQ using patient-level data from the PREMIER (2-year controlled study in 
early RA) and ARMADA (24-week controlled study in longstanding RA) trials. HUI3 
was rescaled to the interval [0,1] and modeled using a beta distribution and logistic 
link function. Normal-linear models were also estimated. Alternative speciﬁcations 
included age, sex, and HAQ-squared as additional predictors. Model parameters were 
estimated using WinBUGS 1.4.3. Models were compared using the deviance informa-
tion criterion (DIC); lesser values imply better ﬁt. Predicted values from beta-logistic 
models were linearly retransformed to the original HUI3 scale. RESULTS: Results 
were similar in early and late RA. Based on DIC, the beta-logistic models were more 
likely to generate the observed data than were the normal-linear models (PREMIER: 
–673.0 vs. –614.4; ARMADA: –226.1 vs. –215.8). Qualitatively, predictions from the 
beta-logistic models differed modestly from the normal-linear model. At low disability 
(HAQ  0.0), predicted HUI3 utilities were 0.75 vs. 0.81 (PREMIER) and 0.74 vs. 
0.79 (ARMADA) for the beta-logistic and normal-linear models, respectively. At high 
disability (HAQ  3.0), predicted HUI3 utilities were –0.03 vs. –0.05 (PREMIER) and 
0.01 vs. 0.01 (ARMADA). Age, sex, and HAQ-squared did not improve DIC. CON-
CLUSION: There is a strong negative relationship between HAQ and HUI3. Although 
the overall relationship is nonlinear, the linear approximation seems close across 
the relevant range of HAQ scores (0–3). Considering the complexity of the GLM 
approach, normal-linear regression may be adequate for cost-effectiveness analyses.
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OBJECTIVES: The analytic hierarchy process (AHP), a technique for multi-criteria 
decision analysis, is increasingly being used to support health care decision making. 
These decisions mainly relate to the application and coverage of health care technolo-
gies, and its use as a patient-reported outcome measure. The objective of this study is 
to review the use of this upcoming technique in health care; the Analytic Hierarchy 
Process. METHODS: We conducted a systematic review of the relevant medical, 
health-economical, psycho-sociological, managerial, and applied mathematical litera-
ture. We used the keywords “Analytic Hierarchy Process” AND (“patient” OR 
“patients” OR “health” OR “health care” OR “medical” OR “clinical” OR “hospi-
tal”) to search in the general topic of the articles within in the databases PubMed and 
Web of Science. RESULTS: We found 57 distinctive AHP applications in health care. 
Of the retrieved applications, 13 % focus on shared decision-making between patient 
and clinician, 25 % on the development of clinical practice guidelines, 5 % on the 
development of medical devices and pharmaceuticals, 44 % on management decisions 
in health care organizations, and 13 % on the development of national health care 
policy. CONCLUSIONS: From the review it is concluded that the AHP is frequently 
used and provides valuable support in complex health care decisions. The AHP is 
suitable to apply in case of complex health care decision problems, a need to improve 
decision making instead of explain decision outcomes, a need to share information 
among experts or between clinicians and patients, and in case of a limited availability 
of informed respondents. We also foresee the use of the AHP in conducting compre-
hensive Health Technology Assessments involving multiple stakeholders. Only for 
these speciﬁc types of decision problems, we recommend the use of the AHP.
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PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS AMONG 
POST-TRANSPLANT OUTCOMES IN END-STAGE RENAL DISEASE
Johnson FR1, Hauber AB1, Mohamed AF1, Gonzalez JM2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI HEalth Solutions, Research 
Triangle Park, NC, USA
The Food and Drug Administration Amendments Act of 2007 requires FDA to develop 
and implement plans for evaluating beneﬁts and risks of new pharmaceuticals. Quan-
titative approaches to comparing therapeutic beneﬁts and risks thus are increasingly 
of interest to regulators and industry decision makers. OBJECTIVES: To quantify 
beneﬁt-risk tradeoff preferences for post-transplant outcomes among chronic kidney-
disease patients at risk for kidney transplant and estimate maximum acceptable 
adverse-event risks for speciﬁed efﬁcacy improvements. METHODS: US residents aged 
18 years or older with a self-reported diagnosis of chronic kidney failure or end-stage 
kidney disease completed a web-enabled survey instrument that presented a series of 
trade-off questions, each including a pair of hypothetical post-transplant outcome 
proﬁles. Each proﬁle was deﬁned by ﬁve efﬁcacy attributes and three life-threatening 
adverse-event attributes. Each subject answered 9 trade-off questions based on a pre-
determined experimental design with known statistical properties. RESULTS: A total 
of 233 subjects completed the survey. Subjects judged life expectancy to be more than 
three times more important than the next most important outcome. There were sig-
niﬁcant differences in preferences between older and younger subjects. Subjects over 
age 54 judged risks of impaired renal function, graft loss, acute rejection, infection, 
and malignancy as similarly important and progressive multifocal leukoencephalopa-
thy (PML) risk as much less important. Subjects under age 54 judged risks of acute 
rejection, malignancy, and PML as unimportant. Maximum acceptable risk of serious 
infection for a one-year increase in expected survival was 8.5% (5.1%–17.7%) and 
1.6% (0.9%–3.1%) for older and younger subjects, respectively. CONCLUSIONS: 
The beneﬁt-risk tradeoff data obtained in this study support valid estimates of 
maximum acceptable adverse-event risks in different patient populations. These esti-
mates of risk tolerance provide a useful quantitative approach to identifying treat-
ments where acceptable risk levels exceed actual risk levels by signiﬁcant margins.
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OBJECTIVES: Many patients experience complex disease courses raising concerns 
about fragmentation of care and continuity. The objective of the present study was 
to explore which dimensions that are important to patients in their experience of 
continuity of care. Patients’ preferences were elicited using a discrete choice experiment 
(DCE). METHODS: 1800 patients were invited to participate in a postal survey 
including three patient groups; diabetics, heart patients and cancer patients. Random 
samples of each of the deﬁned patient groups were recruited through Odense Univer-
sity Hospital given at least one admission during the last two years. The DCE con-
tained ﬁve attributes; 1) Involvement of GP in the patient’s course of disease; 2) 
Arrangement of a contact person at the hospital; 3) Involvement of the patient in the 
decisions; 4) Yearly consultation at hospital; and 5) Distance to hospital. RESULTS: 
Data was collected in the period April-June 2009 and resulted in an overall response 
rate of 67%. Primary analyses of DCE data are promising. All respondents value 
patient involvement in the treatment decision highly whereas the involvement of GPs 
matters less—in particular to diabetic patients and cancer patients. We observe some 
differences in preferences among diabetes compared to the two other patient groups. 
Notably heart and cancer patients ﬁnd the offer of yearly consultation unimportant 
and ﬁnd the arrangement of a contact person objectionable. These two differences 
likely indicate patients’ (dis)satisfaction with the health care system and the current 
organisation of treatment and as such may reﬂect some lack of continuity of care. 
CONCLUSIONS: Worldwide there has been a policy focus on enhancing patients’ 
satisfaction and enhancing continuity of care among patients. The present study con-
tributes to this work by examining what dimensions that are deemed important by 
patients in their experience with the health care system during their disease courses.
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The US Food and Drug Administration recently was granted new authority to regulate 
tobacco-related risks. While the morbidity and mortality beneﬁts of smoking cessation 
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are well established, the value of possible life extensions is not. Estimates of the value 
of a statistical life are of limited relevance to valuing such quality-adjusted longevity 
gains. OBJECTIVES: To estimate older smokers’ willingness to pay (WTP) for quality-
adjusted longevity gains. METHODS: Smokers aged 50–64 completed a computerized 
conjoint-analysis (discrete-choice experiment) survey instrument. Hypothetical longev-
ity proﬁles described restrictions on activities of daily living (ADL) for longevity 
increases between 1 and 4 years. The choice task used to explain to respondents how 
risk reductions could be realized without smoking cessation was through the purchase 
of hypothetical cigarette ﬁlters that had no effect on smoking beneﬁts. The joint 
determination of the type and quantity of ﬁlters was modeled jointly to estimate choice 
of ﬁlter type and demand. WTP for life extensions under speciﬁed ADL restrictions 
then were derived from model parameters. RESULTS: A total of 248 subjects com-
pleted the survey. ADL restrictions are a stronger determinant of WTP than years of 
longevity increases. Valuations of life extensions are positive only for high ADL levels. 
The present-value WTP for a one-year life extension with the ADL level described as 
“You are able to drive and you are able to walk a few blocks” is $126,000 (3% dis-
count rate). For the ADL level “Unable to leave your bed”, the corresponding WTP 
is minus $204,000. CONCLUSIONS: Our results shed new light on the perceived 
value to middle-aged subjects of longevity increases under speciﬁed ADL restrictions. 
The WTP estimates suggest that the net beneﬁts of interventions with modest increases 
in longevity are likely to be positive only if the interventions also yield high quality 
of life.
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BACKGROUND: Since 2006, Dutch children receive a 7-valent pneumococcal con-
jugate vaccine (PCV7) against Streptococcus pneumoniae (pneumococci), a leading 
cause of childhood illnesses. New vaccines, covering a wider range of serotypes, will 
soon be available. OBJECTIVES: To evaluate the cost-effectiveness of 10- and 13-
valent vaccines (PCV10 and PCV13) by calculating quality adjusted life years (QALY) 
and costs, and estimate the cost-utility from the societal perspective. METHODS: A 
Markov model was used to calculate the effects of vaccinating a single cohort of 
newborn children in terms of two non-invasive diseases (pneumonia, acute otitis 
media) and two invasive diseases (meningitis, bacteremia) with associated sequelae 
and mortality. Vaccination effectiveness was estimated using trial data. Scenario 
analysis was conducted to analyze the effects of herd immunity. Probabilistic sensitiv-
ity analysis was carried out on incidences, costs, transition probabilities, utility weights 
and vaccine effectiveness. RESULTS: Assuming equal price per dose, both PCV10 and 
PCV13 were dominant compared to PCV7, with lower costs and more QALYs. Due 
to the larger range of serotypes, PCV13 has the fewest cases of pneumonia, invasive 
diseases and sequelae, and is the most cost-effective treatment, dominant to both other 
treatments. However, the superior effectiveness of PCV10 against the very proliﬁc 
otitis compensates in such a way that the difference in both costs and QALYs between 
PCV10 and PCV13 is much smaller than was expected beforehand. CONCLUSIONS: 
From a cost-utility perspective, PCV7 could be replaced by either one of the new 
vaccines, when they become available. The choice between PCV10 and PCV13 will 
depend primarily on price setting and the importance that is assigned to indirect costs. 
PCV10 prevents more cases of frequent, but cheaper otitis, PCV13 prevents more cases 
of less frequent, but more costly in both money and effects, invasive diseases.
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OBJECTIVES: A vaccine for the prevention of HZ and PHN will soon be available 
in Europe. This study assesses the clinical and economic impact of vaccination in 
Belgium. METHODS: Using a Markov model speciﬁcally developed for Europe, a 
vaccination strategy for the Belgian population aged 60 years was compared to the 
current situation of no vaccination. Most epidemiological, resource utilisation and 
general population data were obtained from Belgian sources. In the absence of Belgian 
data, the proportion of PHN was derived from the General Practitioners Research 
Database analysis in the UK, while HZ/PHN pain split, PHN duration and utility data 
were based on the literature. Outcomes included NNV (numbers needed to vaccinate), 
QALYs gained, HZ and PHN cases avoided, applying a PHN deﬁnition of pain occur-
ring or persisting at least 3 months after rash onset. RESULTS: RESULTS A vaccina-
tion strategy compared to no-vaccination resulted in ICERs of a6,799/QALY gained, 
a1,308/HZ case avoided and a3,842/PHN case avoided over the lifetime of the 60 
population, under a third-party payer perspective. NNV results indicated that 12 and 
35 people must be vaccinated to avoid one case of HZ and PHN respectively. Sub-
group analyses for the 60–69 age group showed ICERs of a5,545/QALY gained, 
a843/HZ case avoided, a2,976/PHN case avoided, and NNVs of 8 and 28 respectively. 
Deterministic sensitivity analyses produced ICERs ranging from a4,959 to a19,052/
QALY gained, with the duration of vaccine efﬁcacy having the biggest impact on 
results. A probabilistic sensitivity analysis showed that the probability of the ICERs 
remaining below a30,000 is 94.5% for the 60 population and 95.9% for the 60–69 
population, conﬁrming the cost-effectiveness of vaccination. CONCLUSIONS: The 
ICERs are well below the commonly accepted threshold of a30,000/QALY gained, 
indicating that a HZ vaccination programme would represent a costeffective interven-
tion for Belgium.
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OBJECTIVES: Following recent successes in reducing measles mortality worldwide, 
the WHO has raised the question of the feasibility and cost-effectiveness of the global 
eradication of measles, allowing the stoppage of routine immunization. We estimated 
the potential economic value of measles eradication for a lower-income country using 
the example of Ghana as a case study. We also considered a post-eradication scenario 
with national stockpiling of a measles vaccine to be used in the event of the re-
 introduction either by accident or bioterrorism. METHODS: We estimated timing of 
measles elimination (cessation of within-country transmission), and the numbers of 
measles cases and deaths from an age-structured dynamic compartmental model. After 
elimination, there would be a residual number of cases imported from neighbors. We 
assumed that global eradication would eliminate this importation beginning in 2020 
through a model horizon of 2049. For Ghana, based on accounting and budget data, 
the estimated cost per routine immunization dose was $2.07 and for doses during 
campaigns was $0.70. RESULTS: The dynamic model predicted that elimination 
would be achieved in Ghana in 2009. Between 2020 and 2049, there would be 1711 
cases and 55 deaths. The aggregate present discounted value (to 2010) of the cost of 
routine immunization over this period would be $25.2 million. If measles were eradi-
cated in 2019 and immunization halted thereafter, Ghana would save this amount. 
However, if there were a perceived need to maintain a stockpile to protect the 20.8 
million children projected to be born over this period, even at $0.70 per dose, it would 
require a shelf life of more than 15 years to be cost-effective. CONCLUSIONS: Despite 
the obvious appeal of the global eradication of measles as a long-term objective, it 
appears unlikely that–even with a post-eradication stockpiling strategy–it would be 
cost-effective to cease ongoing vaccination entirely.
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OBJECTIVES: A novel intradermal vaccine (ID) containing 15 Mg of haemagglutinin 
per dose was speciﬁcally developed to prevent seasonal inﬂuenza in subjects aged 60 
years and over (60). In this population, superior immunogenicity of ID vaccine to 
conventional intramuscular vaccine (IM) has been demonstrated during clinical trials. 
We assessed the clinical outcomes and economic impact of vaccinating 60 with ID 
versus IM vaccines. METHODS: A decision-analytic model compared the cost-
 effectiveness ratios of ID versus IM vaccines. Epidemiological and economic inputs 
were speciﬁc to Slovakia and Czech Republic, whereas vaccine effectiveness rates were 
estimated from international literature and inferred from clinical trials. ID prices were 
hypothetical. Results were reported according to public payer’s perspective. RESULTS: 
In Slovakia, ID vaccination was found to prevent 13,134 inﬂuenza cases, 1,159 hos-
pitalizations and 273 deaths in the 60 population, more than with IM vaccination 
(respectively 11,235 inﬂuenza cases, 991 hospitalizations, 234 deaths). In Czech 
Republic these ﬁgures were respectively 35,691, 3,642 and 584 with ID versus 30,532, 
3,115 and 500 with IM. Higher price of ID versus IM was partially offset by the costs 
saved thanks to disease avoided: an incremental a5 per subject vaccinated with ID in 
Slovakia and a4.4 (CZK118.10) in Czech Republic was required from the payer’s 
perspective. Incremental cost-effectiveness ratios of ID versus IM were a12,852/QALY 
in Slovakia and a10,375/QALY (i.e. CZK278,532/QALY) in Czech Republic. These 
values were below three yearly GDP per capita in these 2 countries and therefore could 
be seen as acceptable for health authorities. In probabilistic sensitivity analyses, 
ID vaccination remained a cost-effective strategy. CONCLUSIONS: In the absence of 
published local guidelines regarding the interpretation of cost-effectiveness ratios, 
we chose to follow WHO guidelines regarding GDP per capita: immunizing the 60 
population with ID in Slovakia and Czech Republic appears as a cost-effective alterna-
tive when compared to IM.
